THERAPY DOSSIER · th-ed5753210a49

Ganoderma lucidum extract delivered as pharmacopuncture

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04029649 ↗PHASE2/PHASE3unknown

Beta-1,3/1,6-D-Glucan From Ganoderma Lucidum Mycelium Extract on Ulcerative Colitis (RCT)

Ulcerative Colitis

Enrolment: 204 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25780708 ↗2014Reported benefit

Ganoderma lucidum Pharmacopuncture for the Treatment of Acute Gastric Ulcers in Rats.

RatChemical/toxinSprague-Dawleyn = 4 groups of 8 rats (32 in total)Acupoint injection at CV12 and ST36After ulcer induction

Model: Ethanol/HCl-induced acute gastric ulcer

Ganoderma lucidum pharmacopuncture at CV12 and ST36 promoted healing of the ethanol-induced acute gastric ulcer with reduced mucosal damage on gross, histological and immunohistochemical assessment.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…